Rosmi F provides a comprehensive lipid management solution that targets multiple lipid parameters simultaneously

Cadila Pharmaceuticals has launched Rosmi F, a fixed-dose combination of Rosuvastatin and Fenofibrate. This therapy has been introduced to address the unmet clinical need in patients suffering from mixed dyslipidemia, a condition marked by elevated low-density lipoprotein (LDL) cholesterol and triglyceride levels that significantly increase cardiovascular risk.

In view of the rising incidence of lifestyle-related disorders such as diabetes, obesity, and cardiovascular diseases, Rosmi F provides a comprehensive lipid management solution that targets multiple lipid parameters simultaneously.

Rosmi F brings together two powerful lipid-lowering agents with complementary mechanisms. Rosuvastatin inhibits HMG-CoA reductase to reduce LDL cholesterol synthesis, while Fenofibrate activates PPAR-α receptors to lower triglycerides and increase HDL-C.

Dr Rajiv I Modi, CMD, Cadila Pharmaceuticals, said, “The introduction of Rosmi F is an important milestone in our efforts to address the growing burden of cardiometabolic disorders in India. Mixed dyslipidemia is a widespread yet often under-managed condition. Rosmi F offers clinicians an effective and scientifically validated tool to improve lipid control and reduce long-term cardiovascular risk. We look forward to its strong adoption and its impact on improving patient outcomes across the country.”